Dynepo Appellate Decision Gives TKT Another Chance Against Amgen Patents
Executive Summary
Transkaryotic Therapies will have a second chance to argue that its gene activated-EPO product Dynepo does not violate patents for Amgen's erythropoietin product Epogen following a Jan. 6 decision by the D.C. federal appellate court
You may also be interested in...
TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model
Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions
TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model
Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions
Wellbutrin SR Patent Case Will Be Early Application Of Festo Ruling
GlaxoSmithKline's defense of its Wellbutrin SR (bupropion sustained release) patents will be an early real world application of the Supreme Court's decision in the Festo case